Hachamovitch Rory, Hayes Sean W, Friedman John D, Cohen Ishac, Berman Daniel S
Cardiovascular Division, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90048, USA.
J Am Coll Cardiol. 2004 Jan 21;43(2):200-8. doi: 10.1016/j.jacc.2003.07.043.
We sought to evaluate the prognostic and cost implications of stress myocardial perfusion single-photon emission computed tomography (SPECT), or MPS, in patients with a high pretest likelihood (>0.85) of coronary artery disease (CAD) with no previous CAD.
Sparse data are available regarding the prognostic performance characteristics of MPS in this patient group.
We followed up 1,270 consecutive patients with no previous revascularization or myocardial infarction (MI), with a pre-exercise tolerance test (ETT) likelihood of CAD > or =0.85, who underwent exercise or adenosine stress MPS (follow-up 94.4% complete; 2.2 +/- 1.2 years; 60 hard events [5.9%, 2.6%/year]). Risk adjustment of survival data was done using Cox proportional hazards analysis. Costs per reclassification of risk were calculated using assumed costs and threshold analyses.
In patients treated medically after MPS, normal MPS had a low risk of cardiac death and hard events (0.6% and 1.3% per year, respectively). With increasing extent and severity of MPS defects, the risk of both cardiac death and hard events increased significantly (p < 0.05). Cox models indicated that the addition of MPS data resulted in incremental prognostic value over pre-MPS data (chi-square increase 48 to 87, p < 0.0001). Compared with strategies of initial referral to ETT in patients able to exercise, initial referral to MPS appeared to be a more cost-effective strategy. Similarly, compared with a strategy of direct referral to catheterization in patients with a high likelihood of CAD, initial referral to MPS is a cost-saving approach.
In patients with a high likelihood of CAD but without known CAD, stress MPS yields incremental value and achieves risk stratification in a cost-effective manner. The current results support a strategy of initial stress imaging in this patient cohort, as a reasonable alternative to direct referral to catheterization or initial ETT.
我们试图评估应力心肌灌注单光子发射计算机断层扫描(SPECT),即心肌灌注显像(MPS),对既往无冠心病但冠心病预测试验前可能性较高(>0.85)患者的预后及成本影响。
关于该患者群体中MPS预后性能特征的数据稀少。
我们对1270例既往无血运重建或心肌梗死(MI)、运动前耐受性试验(ETT)冠心病可能性≥0.85且接受运动或腺苷应力MPS的连续患者进行随访(随访完成率94.4%;2.2±1.2年;60例严重事件[5.9%,2.6%/年])。使用Cox比例风险分析对生存数据进行风险调整。使用假设成本和阈值分析计算每次风险重新分类的成本。
MPS后接受药物治疗的患者中,正常MPS的心脏死亡和严重事件风险较低(分别为每年0.6%和1.3%)。随着MPS缺陷范围和严重程度的增加,心脏死亡和严重事件的风险均显著增加(p<0.05)。Cox模型表明,添加MPS数据比MPS前数据具有更高的预后价值(卡方值从48增加到87,p<0.0001)。与能够运动的患者初始转诊至ETT的策略相比,初始转诊至MPS似乎是一种更具成本效益的策略。同样,与CAD可能性高的患者直接转诊至心导管插入术的策略相比,初始转诊至MPS是一种节省成本的方法。
在CAD可能性高但无已知CAD的患者中,应力MPS具有更高的价值,并以具有成本效益的方式实现风险分层。当前结果支持在该患者队列中采用初始应力成像策略,作为直接转诊至心导管插入术或初始ETT的合理替代方案。